v3.26.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2024
Statement of cash flows [abstract]      
Net (loss)/profit $ (6,936,421) $ 1,011,790 $ (51,159,048)
Non-cash adjustment:      
Fair value (gain)/loss on convertible note (3,357,628) 5,157,397
Fair value loss/(gain) on warrant liability 15,380 (694,516) 306,250
Fair value (gain)/loss on promissory notes (705,565) 300,270
Fair value loss on warrant exchange 185,064
Fair value gain on Psyence Labs Ltd (427,000) (22,967)
Fair value loss on Digital Assets 110,242
Share of losses from Associate 45,239
Gain on debt settlement (281,500)
Share-based compensation 155,341 317,882
Third party advisors share issuance 60,000 241,379
Depreciation 5,266 4,268 240
Foreign exchange 44,979 (9,860) 3,660
Listing expense 41,481,605
Transaction expenses 2,100,830
Changes in working capital:      
Other receivables 27,569 (95,601) 107,622
Loan receivable (252,985)
Prepaids (1,004,061) 70,330 (245,075)
Accounts payable and accrued liabilities 13,444 (360,932) (1,035,498)
Cash used in operating activities (8,143,007) (3,734,238) (2,945,365)
Additions to equipment (229) (9,877) (5,727)
Increase in restricted cash (11,227) (6,353)
Investment in Digital Assets (500,000)
Investment in Psyence Labs Ltd (4,000,000)
Cash used for investing activities (4,511,456) (16,230) (5,727)
Proceeds received from convertible note 1,000,000 2,500,000
Payment of promissory note (150,000)
Net proceeds received from ELOC 13,964,060 6,410,395
Net proceeds received for unit issuances 1,742,051
Cash provided from financing activities 13,964,060 9,152,446 2,350,000
Change in cash and cash equivalents 1,309,597 5,401,978 (601,092)
Cash and cash equivalents, beginning of year 6,135,166 733,188 1,334,280
Cash and cash equivalents, end of year $ 7,444,763 $ 6,135,166 $ 733,188